References
Le Blanc K, Frassoni F, Locatelli F et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579–1586
Jurewicz M, Yang S, Augello A et al (2010) Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 59:3139–3147
Ben Nasr M, Vergani A, Avruch J et al (2015) Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site. Acta Diabetol 52:917–927
D’Addio F, Trevisani A, Ben Nasr M et al (2014) Harnessing the immunological properties of stem cells as a therapeutic option for diabetic nephropathy. Acta Diabetol 51:897–904
Fiorina P, Jurewicz M, Vergani A et al (2011) Targeting the CXCR4–CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. J Immunol 186:121–131
Abdi R, Fiorina P, Adra CN et al (2008) Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 57:1759–1767
Kim N, Cho S-G (2013) Clinical applications of mesenchymal stem cells. Korean J Intern Med 28:387–402
Ben Nasr M, D’Addio F, Usuelli V et al (2015) The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacol Res 98:31–38
Djouad F, Plence P, Bony C et al (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102:3837–3844
Karnoub AE, Dash AB, Vo AP et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557–563
Fiorina P, Voltarelli J, Zavazava N (2011) Immunological applications of stem cells in type 1 diabetes. Endocr Rev 32:725–754
Fiorina P, Jurewicz M, Augello A et al (2009) Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 183:993–1004
Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674–1685
El Haddad N, Heathcote D, Moore R et al (2011) Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood 117:1176–1183
Fiorina P, Vergani A, Dada S et al (2008) Targeting CD22 reprograms b-cells and reverses autoimmune diabetes. Diabetes 57:3013–3024
Keng VW, Rahrmann EP, Watson AL et al (2012) PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. Cancer Res 72:3405–3413
Whitman M, Downes CP, Keeler M et al (1988) Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332:644–646
Folli F, Saad MJA, Backer JM, Kahn CR (1992) Insulin stimulation of phosphatidylinositol 3-kinase activity and association with insulin receptor substrate 1 in liver and muscle of the intact rat. J Biol Chem 267:22171–22177
Folli F, Saad MJ, Backer JM, Kahn CR (1993) Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. J Clin Invest 92:1787–1794
De Oliveira Bravo M, Carvalho JL, Saldanha-Araujo F (2016) Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression. Purinergic Signal 12:595–609
Acknowledgements
Francesca D’Addio is the recipient of a Società Italiana di Diabetologia (SID) Lombardia Grant and of the European Foundation for the Study of Diabetes/European Association for the Study of Diabetes (EFSD/EASD) Rising Star Fellowship grant. Paolo Fiorina is the recipient of an European Foundation for the Study of Diabetes (EFSD)/Sanofi European Research Programme and is supported by an American Heart Association (AHA) Grant-in-Aid. Reza Abdi is the recipient of an American Diabetes Association (ADA) Basic Science Award (1-14-BS-001). We thank Fondazione 'Romeo and Enrica Invernizzi' for the support.
Author’s contribution
C.L. and R.F.M. designed the study, performed experiments, analyzed data and wrote the paper; M.B.N., S.D., M.B., M.M., V.U., B.E.E., F.D.A., A.O.S.-R. and S.P. performed experiments and analyzed data; G.V.Z. coordinated research; P.F. and R.A. designed the study, provided financial support, wrote and edited the paper.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical disclosure
Principles of laboratory animal care (NIH publication No. 86-23, revised 1985) were followed, as well as all applicable institutional guidelines for the care and use of experimental animals.
Informed consent
This study does not involve human subjects. No informed consent needs to be obtained.
Additional information
Managed by Massimo Federici.
Cristian Loretelli and Robert F. Moore contributed equally to this study and are considered co-first authors.
Paolo Fiorina and Reza Abdi should be considered senior co-authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Loretelli, C., Moore, R.F., Ben Nasr, M. et al. Immunoevasion rather than intrinsic oncogenicity may confer MSCs from non-obese diabetic mice the ability to generate neural tumors. Acta Diabetol 54, 707–712 (2017). https://doi.org/10.1007/s00592-017-0967-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-017-0967-0